NCNA

NuCana plc [NCNA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

NCNA Stock Summary

Top 10 Correlated Stocks

NCNA


In the News

07:52 29 Mar 2024 NCNA

Why Is NuCana (NCNA) Stock Up 102% Today?

NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the company's stock changing hands as of this writing.

02:39 29 Mar 2024 NCNA

NuCana: Potential Turnaround In 2024 But Risky

NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to believe that NCNA's current lead candidate, NUC-3373, will be successful. NUC-3373 aims to replace 5-fluorouracil (5FU) by overcoming its numerous limitations. Notably, 5FU is still used in a variety of malignancies. Importantly, 5FU-based chemotherapy regimens remain the cornerstone for treatment of colorectal cancer.

04:01 29 Mar 2024 NCNA

NuCana to Present at the Jefferies London Healthcare Conference

EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies London Healthcare Conference.

08:46 29 Mar 2024 NCNA

Why Is NuCana (NCNA) Stock Down Today?

NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCana is set to attend the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 in Boston, Mass.

11:17 29 Mar 2024 NCNA

Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now

NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

08:00 29 Mar 2024 NCNA

NuCana to Present at the Jefferies Healthcare Conference

EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Healthcare Conference.

09:21 29 Mar 2024 NCNA

Why Is NuCana (NCNA) Stock Down 36% Today?

NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company's European Patent 2955190 isn't valid.

08:00 29 Mar 2024 NCNA

NuCana to Participate in Two Upcoming Investor Conferences

EDINBURGH, United Kingdom, Feb. 28, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will participate in two upcoming investor conferences.

04:30 29 Mar 2024 NCNA

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana's market cap is not reflecting the potential of two other drug candidates NUC-3373 and NUC-7738, currently in Phase 2 trials. The UK and EU proceedings against Gilead for alleged years-long infringement of an EU patent have important hearing dates lined up in January and March 2023.

01:32 29 Mar 2024 NCNA

NuCana PLC Sponsored ADR (NCNA) Upgraded to Buy: What Does It Mean for the Stock?

NuCana PLC Sponsored ADR (NCNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NCNA Financial details

Company Rating
Neutral
Market Cap
15.92M
Income
-27.63M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
28
Optionable
No
Shortable
Yes
Earnings
15 May 2024
P/E
-0.37
Forward P/E
-0.93
PEG
0.07
P/S
-
P/B
0.59
P/C
-
P/FCF
-0.38
Quick Ratio
2.57
Current Ratio
2.57
Debt / Equity
0.03
LT Debt / Equity
0.01
-
-
EPS (TTM)
-0.38
EPS next Y
-0.28
EPS next Q
-
EPS this Y
-21.52%
EPS next Y
-25.71%
EPS next 5Y
-100.79%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-6.06%
SMA50
3.33%
SMA100
-38%
Inst Own
14.95%
Inst Trans
0.57%
ROA
-104%
ROE
-118%
ROC
-1.86%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
52.36M
Shs Float
43.24M
-
-
-
-
Target Price
-
52W Range
0.226-1.43
52W High
-
52W Low
-
RSI
36.19
Rel Volume
0.77
Avg Volume
1.65M
Volume
1.28M
Perf Week
-22.25%
Perf Month
-18.75%
Perf Quarter
-56.66%
Perf Half Y
-55.17%
-
-
-
-
Beta
0.962
-
-
Volatility
0.02%, 0.03%
Prev Close
-15.21%
Price
0.26
Change
-13.48%

NCNA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.67-0.81-0.79-0.620
Operating cash flow per share
-0.75-0.57-0.46-0.450
Free cash flow per share
-0.79-0.61-0.48-0.460
Cash per share
1.632.311.170.810
Book value per share
22.621.270.740
Tangible book value per share
1.872.491.230.70
Share holders equity per share
22.621.270.740
Interest debt per share
0.030.020.01-0.180
Market cap
146.37M124.45M90.88M28.32M0
Enterprise value
95.21M37.74M30.98M-12.95M-16.83M
P/E ratio
-6.84-4.06-2.24-0.880
Price to sales ratio
00000
POCF ratio
-6.14-5.76-3.81-1.220
PFCF ratio
-5.83-5.35-3.65-1.20
P/B Ratio
2.31.251.390.740
PTB ratio
2.31.251.390.740
EV to sales
00000
Enterprise value over EBITDA
-3.98-1.32-0.740.270
EV to operating cash flow
-4-1.75-1.30.560.64
EV to free cash flow
-3.79-1.62-1.240.550.63
Earnings yield
-0.15-0.25-0.45-1.130
Free cash flow yield
-0.17-0.19-0.27-0.840
Debt to equity
0.010.010.010.020.03
Debt to assets
0.010.0100.010.01
Net debt to EBITDA
2.143.031.430.870
Current ratio
10.5412.496.112.841.97
Interest coverage
0003.970
Income quality
1.110.70.590.720.96
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.060.040.030.040.08
Capex to operating cash flow
0.050.080.040.020.02
Capex to revenue
00000
Capex to depreciation
-1.76-1.83-1.13-0.71-0.83
Stock based compensation to revenue
00000
Graham number
5.56.914.743.220
ROIC
-0.34-0.31-0.61-0.820
Return on tangible assets
-0.32-0.3-0.54-0.570
Graham Net
1.732.371.10.580
Working capital
58.97M93.66M59.9M35.61M12.34M
Tangible asset value
59.56M94.48M63.14M36.14M12.76M
Net current asset value
58.41M93.24M59.69M35.17M12.1M
Invested capital
0.010.010.010.020.03
Average receivables
9.9M13.82M12.9M10.84M8.07M
Average payables
2.43M2.33M2.04M3.32M4.09M
Average inventory
-906.6K-13.82K-12.9K-5.67K0
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.34-0.31-0.62-0.830
Capex per share
-0.04-0.04-0.02-0.010

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.29-0.15-0.1-0.130
Operating cash flow per share
-0.13-0.2-0.11-0.190
Free cash flow per share
-0.13-0.2-0.11-0.190
Cash per share
0.810.590.470.340
Book value per share
0.740.610.520.410
Tangible book value per share
0.70.560.470.410
Share holders equity per share
0.740.610.520.410
Interest debt per share
0.10.030.010.010
Market cap
28.35M50.28M32.81M26.58M0
Enterprise value
-12.93M19.88M8.73M9.23M-16.83M
P/E ratio
-0.47-1.6-1.52-0.990
Price to sales ratio
00000
POCF ratio
-4.18-4.87-5.61-2.610
PFCF ratio
-4.11-4.79-5.48-2.590
P/B Ratio
0.741.581.21.220
PTB ratio
0.741.581.21.220
EV to sales
00000
Enterprise value over EBITDA
1.06-2.61-1.74-12.39
EV to operating cash flow
1.91-1.92-1.49-0.91218.56
EV to free cash flow
1.87-1.89-1.46-0.996.72
Earnings yield
-0.54-0.16-0.17-0.250
Free cash flow yield
-0.24-0.21-0.18-0.390
Debt to equity
0.020.020.020.020.03
Debt to assets
0.010.010.010.010.01
Net debt to EBITDA
3.383.994.811.882.39
Current ratio
2.842.732.82.571.97
Interest coverage
-3.67-8.29000
Income quality
0.451.311.081.520.01
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.040.050.060.080.08
Capex to operating cash flow
0.020.020.020.011.26
Capex to revenue
00000
Capex to depreciation
-1.96-1.11-0.94-0.58-0.69
Stock based compensation to revenue
00000
Graham number
2.221.431.11.090
ROIC
-0.39-0.25-0.2-0.3-0.5
Return on tangible assets
-0.27-0.17-0.14-0.21-0.3
Graham Net
0.580.440.360.290
Working capital
35.61M28.78M24.35M18.73M12.34M
Tangible asset value
36.14M29.28M24.83M19.19M12.76M
Net current asset value
35.17M28.38M24.02M18.45M12.1M
Invested capital
0.020.020.020.020.03
Average receivables
11M11.02M11.19M11.75M9.33M
Average payables
5.21M5.25M5.19M4.93M4.27M
Average inventory
-3.53M0000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.39-0.25-0.2-0.31-0.51
Capex per share
00000

NCNA Frequently Asked Questions

What is NuCana plc stock symbol ?

NuCana plc is a GB stock and trading under the symbol NCNA

What is NuCana plc stock quote today ?

NuCana plc stock price is $0.26 today.

Is NuCana plc stock public?

Yes, NuCana plc is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Top Correlated Stocks
Similar Market Cap